MoonLake Immunotherapeutics

NASDAQ:MLTX USA Biotechnology

Market Cap

$1.20 Billion

Market Cap Rank

#9439 Global

#4543 in USA

Share Price

$16.77

Change (1 day)

+0.24%

52-Week Range

$6.25 - $61.99

All Time High

$63.86

MoonLake Immunotherapeutics - Asset Resilience Ratio

Latest as of December 2025: 14.01%

MoonLake Immunotherapeutics (MLTX) has an Asset Resilience Ratio of 14.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

$59.45 Million

Cash + Short-term Investments

Total Assets

$424.43 Million

All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how MoonLake Immunotherapeutics's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down MoonLake Immunotherapeutics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$59.45 Million	14.01%
Total Liquid Assets	$59.45 Million	14.01%

Asset Resilience Insights

Moderate Liquidity: MoonLake Immunotherapeutics has 14.01% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.